Literature DB >> 19086531

Prevalence of hepatitis D virus infection in HBsAg positive subjects in Iran.

Gholamreza Roshandel1, Shahryar Semnani, Nafiseh Abdolahi, Abbas-Ali Keshtkar, Sima Besharat, Hamidreza Joshaghani, Abdolvahab Moradi, Khodaberdi Kalavi, Ali Jabbari, Mohammad Javad Kabir, Seyed Ahmad Hosseini, Seyed Mehdi Sedaqat, Ahmad Danesh, Danial Roshandel, Seyed Mohammad Hedayat-Mofidi.   

Abstract

This study was carried out to determine the seroprevalence of hepatitis D virus among HBsAg positive individuals in the northeast part of Iran. One hundred thirty nine HBsAg positive subjects detected from a population based single stage cluster sampling in Golestan province of Iran were enrolled. All cases were evaluated for the presence of anti-HDV antibodies using commercially available ELISA kits. Logistic regression was used to determine the relationship between independent variables and HDV seropositivity. Of 139 cases, 68 (48.9%) were males and 71 (51.1%) were females. The mean age was 41.89 +/- 11.30 years (25-64 years). Anti-HDV antibody was positive in 8 (5.8%) subjects with female predominance (9.9% versus 1.5%, p = 0.06; odds ratio = 7.32, 95% CI: 0.87-61.23). No significant relationship was seen between anti-HDV seropositivity and demographic factors such as age, place of residence and marital status. These findings showed that HDV infection was endemic in Golestan province (northeast) of Iran. Seroprevalence of Anti-HDV in the present study was higher than some previous studies from other parts of Iran. Our results suggest that the prevalence of HBV/HDV co-infection in Iran has increased during the last decade. Therefore, practitioners and all health care managers should be made aware of the risk of dual infection with HBV and HDV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19086531     DOI: 10.3923/pjbs.2007.1751.1754

Source DB:  PubMed          Journal:  Pak J Biol Sci        ISSN: 1028-8880


  7 in total

1.  Prevalence of hepatitis D virus infection among hepatitis B virus-infected individuals in India.

Authors:  Shankar Lal Jat; Neha Gupta; Tarun Kumar; Swapnil Mishra; Avani S; Vishwajeet Yadav; Amit Goel; Rakesh Aggarwal
Journal:  Indian J Gastroenterol       Date:  2015-04-24

2.  Prevalence of hepatitis d virus infection among hepatitis B virus infected patients in qom province, center of iran.

Authors:  Mohammad-Reza Ghadir; Mojtaba Belbasi; Akram Heidari; Seyed Saeid Sarkeshikian; Alireza Kabiri; Amir Hossein Ghanooni; Abolfazl Iranikhah; Maryam Vaez-Javadi; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2012-03-28       Impact factor: 0.660

3.  Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis.

Authors:  Neda Amini; Seyed Moayed Alavian; Ali Kabir; Seyed Hossein Aalaei-Andabili; Seyed Yasser Saiedi Hosseini; Mario Rizzetto
Journal:  Hepat Mon       Date:  2013-01-06       Impact factor: 0.660

4.  Clinical Features and Seroepidemiology of Anti-HDV Antibody in patients With Chronic Hepatitis B Virus Infection in Iran: A Meta-Analysis.

Authors:  Neda Amini; Seyed Moayed Alavian; Ali Kabir; Seyed Yaser Saiedi Hosseini; Seyed Hossein Aalaei Andabili
Journal:  Hepat Mon       Date:  2011-12-20       Impact factor: 0.660

5.  Prevalence of hepatitis d virus infection among patients with chronic hepatitis B attending birjand hepatitis clinic (East of iran) in 2012.

Authors:  Masood Ziaee; Ghodsieh Azarkar
Journal:  Hepat Mon       Date:  2013-08-25       Impact factor: 0.660

6.  Prevalence of HIV and Hepatitis B, C, D Infections and Their Associated Risk Factors among Prisoners in Southern Khorasan Province, Iran.

Authors:  Masood Ziaee; Gholamreza Sharifzadeh; Mohammad Hasan Namaee; Mohammad Fereidouni
Journal:  Iran J Public Health       Date:  2014-02       Impact factor: 1.429

7.  Evidence of Hepatitis D Virus Infection in HBsAg Positive Subjects of Mashhad, North-East of Iran.

Authors:  Hosain Nomanee; Sina Rostami; Mohammad Taghi Shakeri; Zahra Meshkat
Journal:  Jundishapur J Microbiol       Date:  2015-10-20       Impact factor: 0.747

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.